Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Common Equity (2016 - 2025)

Vistagen Therapeutics (VTGN) has disclosed Common Equity for 13 consecutive years, with $50.9 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 37.23% to $50.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $50.9 million through Dec 2025, down 37.23% year-over-year, with the annual reading at $70.4 million for FY2025, 38.41% down from the prior year.
  • Common Equity hit $50.9 million in Q4 2025 for Vistagen Therapeutics, down from $66.3 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $123.3 million in Q4 2023 to a low of $6.8 million in Q2 2023.
  • Historically, Common Equity has averaged $65.7 million across 5 years, with a median of $68.4 million in 2025.
  • Biggest five-year swings in Common Equity: skyrocketed 1810.19% in 2021 and later crashed 85.13% in 2023.
  • Year by year, Common Equity stood at $80.0 million in 2021, then tumbled by 74.15% to $20.7 million in 2022, then surged by 496.31% to $123.3 million in 2023, then crashed by 34.2% to $81.1 million in 2024, then crashed by 37.23% to $50.9 million in 2025.
  • Business Quant data shows Common Equity for VTGN at $50.9 million in Q4 2025, $66.3 million in Q3 2025, and $56.8 million in Q2 2025.